Browse > Article
http://dx.doi.org/10.7314/APJCP.2014.15.22.9615

Lack of Prognostic Value of Human Epidermal Growth Factor- Like Receptor 2 Status in Inflammatory Breast Cancer (IBC): a Meta-analysis  

Li, Xiu-Juan (Department of General Surgery, Jiangsu Cancer Hospital, The Affiliated Hospital of Nanjing Medical University)
Zha, Quan-Bin (Department of Oncology, Jintan Hospital Affiliated to Jiangsu University)
Xu, Xin-Yu (Department of Pathology, Jiangsu Cancer Hospital, The Affiliated Hospital of Nanjing Medical University)
Xia, Lei (Department of Pathology, Jiangsu Cancer Hospital, The Affiliated Hospital of Nanjing Medical University)
Zhang, Zhe (Department of Pathology, Jiangsu Cancer Hospital, The Affiliated Hospital of Nanjing Medical University)
Ren, Zhao-Jun (Department of Pathology, Jiangsu Cancer Hospital, The Affiliated Hospital of Nanjing Medical University)
Tang, Jin-Hai (Department of General Surgery, Jiangsu Cancer Hospital, The Affiliated Hospital of Nanjing Medical University)
Publication Information
Asian Pacific Journal of Cancer Prevention / v.15, no.22, 2014 , pp. 9615-9619 More about this Journal
Abstract
Inflammatory breast cancer (IBC) is a rare, aggressive form of breast cancer which is more likely to be her-2/neu amplified. While the her-2/neu status has been utilised to predict prognosis, the published data are inconsistent. The present meta-analysis was conducted to determine whether the her-2/neu status predicts outcomes. Papers were selected from the PubMed database based on defined inclusion and exclusion criteria. Parameters such as total patients, follow-up time and outcome statistics (i.e. overall survival (OS), relapse-free survival (RFS) were collected. The analysis included 6 studies with 2,838 IBC patients. The summary hazards ratio (HR) estimating the association of OS with HER-2-positive disease was 0.96 (95% confidence interval (95%CI: 0.85-1.10)), with similar findings for RFS (HR=0.81, 95%CI: 0.61-1.09). No obvious statistical heterogeneity was detected. This meta-analysis suggests that HER-2-positive status is not an independent adverse prognostic factor for survival among IBC patient cases.
Keywords
Human epidermal growth factor-like receptor 2; inflammatory breast cancer; meta-analysis; prognosis;
Citations & Related Records
Times Cited By KSCI : 1  (Citation Analysis)
연도 인용수 순위
1 Abdul MNA, Razak ZA, Hussain RM, et al (2013). Quantification of Her-2/Neu gene in breast cancer patients using real timepolymerase chain reaction (Q-PCR) and correlation with immunohistochemistry findings. Asian Pac J Cancer Prev, 14, 1655-9.   DOI
2 Begg CB, Mazumdar M (1994). Operating characteristics of a rank correlation test for publication bias. Biometrics, 50, 1088-101.   DOI   ScienceOn
3 Cabioglu N, Gong Y, Islam R (2007). Expression of growth factor and chemokine receptors: new insights in the biology of inflammatory breast cancer. Ann Oncol, 18, 1021-9.   DOI
4 Chaher N, Arias-Pulido H, Terki N, et al (2012). Molecular and epidemiological characteristics of inflammatory breast cancer in Algerian patients. Breast Cancer Res Treat, 131, 437-44.   DOI
5 Colpaert CG, Vermeulen PB, Benoy I, et al (2003). Inflammatory breast cancer shows angiogenesis with high endothelial proliferation rate and strong E-cadherin expression. Br J Cancer, 88, 718-25.   DOI
6 Dawood S, Broglio K, Gong Y, et al (2008). Prognostic Significance of HER-2 Status in women with inflammatory breast cancer. Cancer, 112, 1905-11.   DOI
7 Ellis GK, Barlow WE, Gralow JR, Hortobagyi GN, et al (2011). Phase III comparison of standard doxorubicin and cyclophosphamide versus weekly doxorubicin and daily oral cyclophosphamide plus granulocyte colony-stimulating factor as neoadjuvant therapy for inflammatory and locally advanced breast cancer: SWOG 0012. J Clin Oncol, 29, 1014-21.   DOI
8 Gianni L, Pienkowski T, Im YH (2012). Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomized multicentre, openlabel, phase 2 trial. Lancet Oncol, 13, 25-32.   DOI
9 Hance KW, Anderson WF, Devesa SS (2005). Trends in inflammatory breast carcinoma incidence and survival: the surveillance, epidemiology, and end results program at the national cancer institute. J Natl Cancer Inst, 97, 966-75.   DOI
10 Higgins JP, Thompson SG, Deeks JJ, et al (2003) Measuring inconsistency in meta-analyses. BMJ, 327, 557-60.   DOI   ScienceOn
11 Kim T, Lau J, Erban J (2006). Lack of uniform diagnostic criteria for inflammatory breast cancer limits interpretation of treatment outcomes:a systematic review. Clinical Breast Cancer, 7, 386-95.   DOI
12 Kleer CG, Zhang Y, Pan Q, et al (2002). WISP3 is a novel tumor suppressor gene of inflammatory breast cancer. Oncogene, 21, 3172-80.   DOI
13 Labidi SI, Mrad K, Mezlini A, et al (2008). Inflammatory breast cancer in Tunisia in the era of multimodality therapy. Ann Oncol, 19, 473-80.
14 Li J, Gonzalez-Angulo AM, Allen PK, et al (2011). Triplenegative subtype predicts poor overall survival and high locoregional relapse in inflammatory breast cancer. Oncol, 16, 1675-83.   DOI
15 Low JA, Berman AW, Steinberg SM, et al (2004). Long-term follow-up for locally advanced and inflammatory breast cancer patients treated with multimodality therapy. J Clin Oncol, 22, 4067-74.   DOI
16 Mehta RS, Schubbert T, Kong K (2008). Trastuzumab in inflammatory breast cancer. Ann Oncol, 19, 1815-7.   DOI
17 Panades M, Olivotto IA, Speers CH, et al (2004). Evolving treatment strategies for inflammatory breast cancer:a population-based survival analysis. J Clin Oncol, 23, 1941-50.
18 Romond EH, Perez EA, Bryant J, et al (2005). Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med, 353, 1673-84.   DOI   ScienceOn
19 Rehman S, Reddy CA, Tendulkar RD (2012). Modern outcomes of inflammatory breast cancer. Int J Radiat Oncol Biol Phys, 84, 619-24.   DOI
20 Romond EH, Perez EA, Bryant J (2005). Trastuzumab plus adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med, 353, 1673-84.   DOI   ScienceOn
21 Sawaki M, Ito Y, Akiyama F, et al (2006). High prevalence of HER-2/neu and p53 overexpression in inflammatory breast cancer. Breast Cancer, 13, 172-8.   DOI
22 Slamon DJ, Clark GM, Wong SG, et al (1987). Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science, 235, 177-82.   DOI   ScienceOn
23 Sutherland S, Ashley S, Walsh G, et al (2010). Inflammatory breast cancer-the royal marsden hospital experience. Cancer, 116, 2815-20.   DOI   ScienceOn
24 Tanner M, Isola J, Wiklund T (2006). Topoisomerase IIa gene amplification predicts favorable treatment response to tailored and dose-escalated anthracycline-based adjuvant chemotherapy in HER-2/neu-amplified breast cancer: scandinavian breast group trial 9401. J Clin Oncol, 24, 2428-36.   DOI
25 Tierney JF, Stewart LA, Ghersi D, et al (2007). Practical methods for incorporating summary time-to-event data into metaanalysis. Trials, 8, 16.   DOI   ScienceOn
26 Tobias A (1999). Assessing the influence of a single study in the meta-anyalysis estimate. Stata Technical Bulletin, 8, 15-27.
27 Zell JA, Tsang WY, Taylor TH, et al (2009). Prognostic impact of human epidermal growth factor-like receptor 2 and hormone receptor status in inflammatory breast cancer (IBC): analysis of 2,014 IBC patient cases from the California cancer registry. Breast Cancer Res, 11, 9.
28 Turpin E, Bieche I, Berthaeau P (2002). The increased incidence of ERBB2 over expression and TP53 mutation in inflammatory breast cancer. Oncogene, 21, 7593-7.   DOI
29 Van Golen KL, Wu ZF, Qiao XT, et al (2000). RhoC GTPase, a novel transforming oncogene for human mammary epithelial cells that partially recapitulates the inflammatory breast cancer phenotype. Cancer Res, 60, 5832-8.